Consolidation Therapy will consist of high dose methotrexate (HDMTX) (every other week for 4 doses); daily mercaptopurine and IT chemotherapy on the same dates of HDMTX. Standard and high-risk patients will also receive pegaspargase. Dasatinib will continue for patients with ABL1-class fusions. Ruxolitinib will continue for patients with activation of JAK-STAT signaling and Day 15 MRD ≥5% or Day 42 MRD ≥1% (or for LLy patients who do not qualify complete response at the end of Remission Induction) and all cases with ETP ALL.